Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News |

Request a free trial

April 24, 2008

Advance in Small Cell Lung Cancer (SCLC)?
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Expert Contributor

Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218

April 22, 2008

Thalidomide (Celgene) use to be liberalized in Europe
Analysis of: Thalidomide Gets Boost in Europe | online.wsj.com
Author: GLG Expert Contributor

Thalidomide literally started the improved outlook in MM along with, and followed by Velcade, Revlimid and Stem Cell transplants. To now have increased access in Europe should open up that market eventhough the other agents are in widespread use (I think)

April 22, 2008

Wellpoint restricting epo products. Am I surprised?? No!!
Analysis of: WellPoint likely to follow FDA on anemia drugs | www.reuters.com
Author: GLG Expert Contributor

A major insurer (Wellpoint) is using the guidelines of the FDA to restrict erythropoietin (Epo) use.

April 21, 2008
Why Xeloda can't eliminate 5FU
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.

Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight

April 21, 2008

Roche's Xeloda to gain more use in frontline treatment of m-CRC
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor

Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...

April 18, 2008

XELOX=FOLFOX! Score one for Roche!
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor

In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.

April 16, 2008
Non small cell lung cancer has little to be excited about
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.

Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy

April 15, 2008

Novartis initiated, positive in randomized phase II trial- I think they (we) may have something!
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: GLG Expert Contributor

"ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death." It is being combined with Taxol and carboplatin in a randomized phase III study.

April 15, 2008

Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor

Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)

April 14, 2008

Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
Analysis of: U.S. Reps give boost to physician-owned hospitals | www.fiercehealthcare.com
Author: GLG Expert Contributor

2 Texas U.S. Reps think that physcian owned hospitals are OK?

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 728

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-06T21:45:17.077

GLG News by Oncologists who Treat Hematologic Malignancies (US)

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare